CGT Research Outlook Technology Report 2024: Capacity and Capability Expansion for CDMOs, Technology Licensing Partnerships, Shift Towards CGT Development for Chronic Diseases
30. August 2024 06:46 ET
|
Research and Markets
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "CGT Research Outlook and Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The report covers the...
Global Allogeneic Cell Therapy Pipeline Report 2024: Clinical Progress, Treatment Efficacy, and Commercial Potential
23. April 2024 09:53 ET
|
Research and Markets
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Allogeneic Cell Therapies - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering Allogeneic cell therapies represent...
Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
27. September 2023 10:12 ET
|
The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...
Cell therapy Manufacturing Market to Surpass US$ 11,633.8 Million by 2030, Says Coherent Market Insights (CMI)
24. Februar 2023 08:30 ET
|
CMI
Burlingame, Feb. 24, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global cell therapy manufacturing market is estimated to be valued at US$ 3,755.4 million in 2022 and is...
Global Allogeneic Cell Therapy Market Size-Forecasts to 2027
22. August 2022 11:31 ET
|
Global Market Estimates
Brooklyn, New York, Aug. 22, 2022 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Allogeneic Cell Therapy Market is projected to grow...
Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications
12. Mai 2021 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors
07. Mai 2020 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting
29. April 2020 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
30. Januar 2020 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
13. Januar 2020 08:00 ET
|
Rubius Therapeutics
RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply...